Pseudotumor cerebri surgery: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Pseudotumor cerebri}} {{CMG}}; {{AE}} ==Overview== Surgical intervention is not recommended for the management of [disease name]. OR Surgery is not the first-l..." |
No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Indications== | ==Indications== | ||
Surgery is not the first-line treatment option for patients with pseudotumor cerebri. Surgery is usually reserved for patients with either: | |||
* Progress of visual field loss despite medical treatment with maximum dosage | |||
* Visual acuity loss which is the result of papilledema | |||
* Resistant headache | |||
* | * hypotesion(51) | ||
* | |||
* | |||
* | |||
==Surgery== | ==Surgery== | ||
==Contraindications== | ==Contraindications== |
Revision as of 14:56, 30 July 2018
Pseudotumor cerebri Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Pseudotumor cerebri surgery On the Web |
American Roentgen Ray Society Images of Pseudotumor cerebri surgery |
Risk calculators and risk factors for Pseudotumor cerebri surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Indications
Surgery is not the first-line treatment option for patients with pseudotumor cerebri. Surgery is usually reserved for patients with either:
- Progress of visual field loss despite medical treatment with maximum dosage
- Visual acuity loss which is the result of papilledema
- Resistant headache
- hypotesion(51)